Axsome Therapeutics announced that the company’s AXS-05 met the primary endpoint in the ADVANCE-1 Phase II/III clinical trial for agitation in patients with Alzheimer’s disease.
The second round of dosing in healthy Seattle volunteers for Moderna’s mRNA-1273 vaccine candidate against COVID-19 has begun. The Phase 1 study is being conducted by the National Institutes of Health (NIH).
Sanofi’s investigational Bruton’s tyrosine kinase inhibitor SAR442168 hit the mark in a mid-stage multiple sclerosis trial.
The U.S. Food and Drug Administration approved Imbruvica (ibrutinib) in combination with Rituxan (rituximab) for chronic lymphocytic leukemia or small lymphocytic lymphoma patients who are new to therapy.
Bristol-Myers Squibb and Exelixis are eying potential approval of a combination therapy for renal cell carcinoma following results from a late-stage study that showed a combination of Opdivo and Cabometyx met the primary endpoint of progression-free survival.
Moderna Inc. announced an agreement for a commitment of up to $483 million from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate development of the company’s mRNA vaccine candidate, mRNA-1273, against the novel coronavirus (SARS-CoV-2).
Sunovion Pharmaceuticals Inc. announced that results of a four-week pivotal study (SEP361-201) evaluating the safety and efficacy of SEP-363856 in patients with schizophrenia were published online in the New England Journal of Medicine.
Cambridge, Massachusetts-based Moderna is one of the first companies to move a vaccine against COVID-19 into clinical trials.
According to the World Health Organization (WHO), there are more than 70 potential vaccines under development, with three already in clinical trials.
A preliminary analysis of late-stage trial data showed that BeiGene’s investigational checkpoint inhibitor tislelizumab is hitting the mark as a potential first-line treatment in patients with non-squamous non-small cell lung cancer (NSCLC).
